Literature DB >> 11830503

Overexpression of ornithine decarboxylase enhances endothelial proliferation by suppressing endostatin expression.

Takahiro Nemoto1, Hisae Hori, Masataka Yoshimoto, Yousuke Seyama, Shunichiro Kubota.   

Abstract

Angiogenesis, an essential process for tumor growth, is regulated by endothelial proliferation factors and their inhibitors such as endostatin. Endostatin, a carboxyl-terminal fragment of type XVIII collagen, inhibits endothelial proliferation, angiogenesis, and tumor growth. Ornithine decarboxylase (ODC), a molecule that is overexpressed in various cancers, is associated with promoting tumor growth and angiogenesis. We found that ODC-overexpressing human cancer cells and breast cancer specimens showed suppressed expression of type XVIII collagen and endostatin. We hypothesized that ODC overexpression may facilitate angiogenesis in tumors by suppressing endostatin expression. ODC-overexpressing COS cells, which showed suppressed type XVIII collagen and endostatin expression, were established. Conditioned media derived from these cells, containing decreased levels of endostatin, induced significant endothelial proliferation. ODC-overexpressing cells, when transplanted into nude mice, suppressed type XVIII collagen expression and promoted neovascularization in vivo. Thus, overexpression of ODC facilitates endothelial proliferation by suppressing endostatin expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830503     DOI: 10.1182/blood.v99.4.1478

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Untargeted and stable isotope-assisted metabolomic analysis of MDA-MB-231 cells under hypoxia.

Authors:  Jie Yang; Jianhua Cheng; Bo Sun; Haijing Li; Shengming Wu; Fangting Dong; Xianzhong Yan
Journal:  Metabolomics       Date:  2018-02-27       Impact factor: 4.290

2.  Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells.

Authors:  Qingsong Zhu; Lihua Jin; Robert A Casero; Nancy E Davidson; Yi Huang
Journal:  Breast Cancer Res Treat       Date:  2012-09-14       Impact factor: 4.872

3.  Treatment of prostate cancer cells with adenoviral vector-mediated antisense RNA using androgen-dependent and androgen-independent promoters.

Authors:  Wei Li
Journal:  Med Oncol       Date:  2009-06-11       Impact factor: 3.064

4.  Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors.

Authors:  George Wilding; David King; Kendra Tutsch; Marcia Pomplun; Chris Feierabend; Dona Alberti; Rhoda Arzoomanian
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

5.  Downregulation of tumstatin expression by overexpression of ornithine decarboxylase.

Authors:  Wei Wang; Chun-Xiao Xu; Guo-Sheng Hou; You-Gen Chen; Jia-Xuan Xin; Xian-Xi Liu
Journal:  Oncol Rep       Date:  2013-08-29       Impact factor: 3.906

6.  Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential cellular gene expression in response to enterovirus 71 infection.

Authors:  Wai Fook Leong; Vincent T K Chow
Journal:  Cell Microbiol       Date:  2006-04       Impact factor: 3.715

7.  Downregulation of MTAP promotes Tumor Growth and Metastasis by regulating ODC Activity in Breast Cancer.

Authors:  Ying Zhang; Tian-Tian Zhang; Lin Gao; Ya-Nan Tan; Yu-Ting Li; Xiang-Yu Tan; Tu-Xiong Huang; Hua-Hui Li; Feng Bai; Chang Zou; Xin-Hai Pei; Bin-Bin Tan; Li Fu
Journal:  Int J Biol Sci       Date:  2022-04-24       Impact factor: 10.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.